Consistently, Sorafenib, the inhibitor of Raf, inhibited beta-catenin/TCF signaling in the tumorigenesis of HCC [9], suggesting that beta-catenin/TCF signaling could be regulated by Ras. The gene discussed is HNF4A; the disease is hepatocellular carcinoma.